Enliven Therapeutics amends 8-K; corrected Q3 2025 results PR

Rhea-AI Filing Summary

Enliven Therapeutics (ELVN) filed an 8‑K/A to amend its November 12, 2025 current report, correcting the press release attached as Exhibit 99.1.

The corrected release covers financial results for the quarter ended September 30, 2025. Information in Items 2.02 and 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

true000167261900016726192025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Enliven Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-39247	81-1523849
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6200 Lookout Road
Boulder, Colorado				80301
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: 720 647-8519

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ELVN		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

Enliven Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to the Current Report on Form 8-K originally filed by the Company with the Securities and Exchange Commission on November 12, 2025 to correct the press release attached as Exhibit 99.1 and incorporated herein by reference.

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, the Company issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		Press Release issued on November 12, 2025 (Corrected)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Enliven Therapeutics, Inc.
Date:	November 12, 2025	By:	/s/ Samuel Kintz
		Name:	Samuel Kintz
		Title:	President and Chief Executive Officer

FAQ

What did Enliven Therapeutics (ELVN) file?

An 8-K/A amending a prior report to correct the press release attached as Exhibit 99.1.

Which period do the results relate to for ELVN?

The corrected press release covers results for the quarter ended September 30, 2025.

When was the press release issued by ELVN?

The press release was issued on November 12, 2025.

Is the information considered filed or furnished?

Information in Items 2.02 and 9.01 (including Exhibit 99.1) is furnished, not filed.

What is ELVN’s trading venue and symbol?

Common stock trades on The Nasdaq Global Select Market under the symbol ELVN.

Who signed the 8-K/A for Enliven Therapeutics?

Samuel Kintz, President and Chief Executive Officer, signed on November 12, 2025.